Commentary: Value Frameworks Are Here: What To Do About Them?
Precision Health Economics’ Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in a new article for Pharmaceutical Commerce.
Commentary: To Prevent Another EpiPen Controversy, the Government Should Step In
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”
Commentary: Concierge Care Can Help Indigent Uninsured
Precision Health Economics’ Dana Goldman offers his latest opinion piece for the New York Times,”Hospital Care for Those Who Can Afford It Helps Care for Those Who Can’t.” In his commentary, Dr. Goldman suggests that concierge care may paradoxically be the best hope for ensuring continued access to healthcare for the indigent uninsured.
Biosimilar Expert Schafer Interviewed for BioPharm Insight
Precision for Value thought leader Jeremy Schafer was recently interviewed by BioPharm Insight’s Reynald Castaneda, providing his perspective into projected competition in the biosimilar marketplace.
Commentary: Anti-TNF Biosimilars In Europe: What Matters Beyond Price?
In the latest edition of Life Science Leader, Precision’s Andre Pinheiro, Mansi Vithlani, Kyle Sarnataro, and Alex Grosvenor examine the introduction of Anti-TNF Biosimilars in Europe.